{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:02:53Z","timestamp":1785934973411,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["N01MH90001"],"award-info":[{"award-number":["N01MH90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.schres.2014.12.024","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T12:48:36Z","timestamp":1419943716000},"page":"429-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data"],"prefix":"10.1016","volume":"161","author":[{"given":"Shinichiro","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Fervaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Plitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ku","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Caravaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Mihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gerretsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Mulsant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2014.12.024_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.12.024_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"22","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"3","key":"10.1016\/j.schres.2014.12.024_bb0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0920-9964(94)90017-5","article-title":"Specificity of the Calgary Depression Scale for schizophrenics","volume":"11","author":"Addington","year":"1994","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2014.12.024_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.09m05258gre","article-title":"Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia","volume":"72","author":"Addington","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.12.024_bb0025","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"8","key":"10.1016\/j.schres.2014.12.024_bb0030","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.12.024_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0447.1975.tb00002.x","article-title":"Quantitative rating of depressive states","volume":"51","author":"Bech","year":"1975","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2014.12.024_bb0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2014.12.024_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0920-9964(95)00107-7","article-title":"Depression in schizophrenia: a comparison of three measures","volume":"20","author":"Collins","year":"1996","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2014.12.024_bb0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.schres.2005.06.001","article-title":"Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients","volume":"78","author":"Dollfus","year":"2005","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2014.12.024_bb0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.schres.2013.10.021","article-title":"Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study","volume":"151","author":"Fervaha","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2014.12.024_bb0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0022-3956(93)90037-3","article-title":"Exactly what does the Hamilton Depression Rating Scale measure?","volume":"27","author":"Gibbons","year":"1993","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2014.12.024_bb0065","series-title":"Dose Equivalents of Psychotropic Drugs Tokyo: Seiwa Press","author":"Inagaki","year":"2012"},{"issue":"9","key":"10.1016\/j.schres.2014.12.024_bb0070","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.12.024_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/11586450-000000000-00000","article-title":"Managing suicide risk in patients with schizophrenia","volume":"25","author":"Kasckow","year":"2011","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.schres.2014.12.024_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2014.12.024_bb0085","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.comppsych.2013.11.002","article-title":"Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine","volume":"55","author":"Kim","year":"2014","journal-title":"Compr. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.12.024_bb0090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0924-9338(00)00232-7","article-title":"Comparison of four scales measuring depression in schizophrenic inpatients","volume":"15","author":"Kontaxakis","year":"2000","journal-title":"Eur. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.12.024_bb0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"9896","key":"10.1016\/j.schres.2014.12.024_bb0095","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.schres.2014.12.024_bb0105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.schres.2014.12.024_bb0110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.schres.2014.12.024_bb0115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4088\/JCP.v65n0416","article-title":"Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2014.12.024_bb0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF00386061","article-title":"Dimensions of the Hamilton Depression Scale. Factor analysis studies","volume":"234","author":"Maier","year":"1985","journal-title":"Eur. Arch. Psychiatry Neurol. Sci."},{"issue":"4","key":"10.1016\/j.schres.2014.12.024_bb0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.12.024_bb0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/ajp.152.2.183","article-title":"Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk\u2013benefit assessment","volume":"152","author":"Meltzer","year":"1995","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.12.024_bb0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2014.12.024_bb0140","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1034\/j.1600-0447.2003.00132.x","article-title":"Depression and subjective quality of life in chronic phase schizophrenic patients","volume":"108","author":"Reine","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2014.12.024_bb0145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1176\/appi.ps.55.5.540","article-title":"An exploratory analysis of correlates of recovery","volume":"55","author":"Resnick","year":"2004","journal-title":"Psychiatr. Serv."},{"issue":"12","key":"10.1016\/j.schres.2014.12.024_bb0150","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2014.12.024_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/oxfordjournals.schbul.a033362","article-title":"Depression during the longitudinal course of schizophrenia","volume":"25","author":"Sands","year":"1999","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2014.12.024_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2014.12.024_bb0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/026988110101500209","article-title":"Suicide and schizophrenia","volume":"15","author":"Siris","year":"2001","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2014.12.024_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2014.12.024_bb0180","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.55.3.250","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"55","author":"Tollefson","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2014.12.024_bb0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0006-3223(99)00049-9","article-title":"The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone","volume":"46","author":"Tollefson","year":"1999","journal-title":"Biol. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414007567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414007567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:25:20Z","timestamp":1760297120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414007567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":36,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0920996414007567"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.12.024","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}